The therapeutic effects of mirodenafil were supported by the enhanced cognitive behavior and the reduction in both Aβ and phosphorylated tau levels in the mirodenafil-treated APP-C105 AD mouse model. The gene discussed is MAPT; the disease is Alzheimer disease.